basonuclin zinc finger protein 2Genealiases: BSN2 · LUTO · bn2
Q-omics provides the consensus-scored BNC2 profile across patient tissues and cancer cell-line models. BNC2 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, BNC2 is differentially expressed in 14, with the highest sampling consensus in UCEC. Additionally, BNC2 RNA expression shows 22,805 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight UVM, UCEC, and GBM as cancer lineages where BNC2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for BNC2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes BNC2 survival associations across molecular data types. BNC2 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (12) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible BNC2 RNA expression–survival associations across cancer types. High BNC2 expression shows unfavorable associations in UVM, LUAD, UCEC and BLCA, but favorable associations in HNSC and UCS. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify UVM as the clearest survival context for BNC2 RNA expression.
This table summarizes BNC2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 2. The strongest signals are observed in BLCA for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for BNC2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. BNC2 shows lower tumor expression in UCEC, BLCA, COAD, THCA, STAD and READ. The UCEC box plot shows higher BNC2 RNA expression in normal versus tumor tissue (log2 FC = −4.297, t-test p < 0.001).
This table shows molecular features associated with BNC2 in patient tissues and cancer cell lines. In patient samples, BNC2 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, BNC2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in BONE and BREAST.
